Groundbreaking research from the Schwarz Lab at Boston Children’s Hospital has identified a novel therapeutic target that could halt the progression of vision loss in patients with Autosomal Dominant Optic Atrophy (ADOA). The study, recently published in the Journal of Clinical Investigation, highlights the role of a specific protein, SARM1, in the degeneration of retinal ganglion cells (RGCs), the neurons responsible for transmitting visual information from the eye to the brain.
ADOA, or Kjer Disease, is the most common genetic optic neuropathy, typically caused by mutations in the OPA1 gene that disrupt mitochondrial function. This disruption leads to the progressive death of RGCs, resulting in irreversible vision loss. While most therapeutic approaches have focused on keeping these cells alive or slowing the damage, the new research suggests a different strategy: turning off the molecular switch that triggers cell death.
SARM1 is known to initiate axon degeneration, the process by which the signal-sending part of a nerve cell breaks down. In ADOA, the activation of SARM1 is a critical step in the damage to RGCs. The researchers discovered that by deleting or disabling the SARM1 protein in a mouse model carrying the OPA1 mutation, the RGCs remained functional, and the mice retained their vision.
This discovery represents a significant paradigm shift in the approach to treating neurodegenerative diseases like ADOA. Instead of merely managing the symptoms or slowing the decline, inhibiting SARM1 could potentially stop the degenerative process entirely. The Schwarz Lab is now exploring whether SARM1 can be effectively turned off using therapeutics, rather than relying solely on genetic manipulation.
The team is currently evaluating ASHA-624, a new drug designed to block SARM1 by locking the protein into an inactive state. If successful in laboratory tests, the next step will be to evaluate the drug's efficacy in clinical trials with human patients. For families affected by ADOA, this research offers a renewed sense of hope. Early genetic diagnosis combined with targeted therapies like SARM1 inhibitors could one day provide a real chance of preserving vision for those at risk of this debilitating condition.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.